Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

ZL-6201

Antibody-drug conjugate · Cytotoxic, directed at leucine-rich repeat-containing protein 15 (LRRC15) · developed by Zai Lab Co.

Phase 1 Most advanced trial
ZLAB Developer
1 Registered trials

What is ZL-6201?

ZL-6201 is an antibody-drug conjugate that pairs a humanized antibody binding LRRC15, a tumor-associated antigen expressed on tumor cells and cancer-associated fibroblasts, with the camptothecin topoisomerase-1 inhibitor C24 through a protease-cleavable linker. After internalization, the released payload inhibits topoisomerase I, causing cell cycle arrest and apoptosis. It is studied in solid tumors and sarcomas.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Antibody-drug conjugate
Targets
leucine-rich repeat-containing protein 15 (LRRC15), DNA topoisomerase I (TOP1) (secondary target)
Mechanism
Cytotoxic, directed at leucine-rich repeat-containing protein 15 (LRRC15)
Pathways
DNA replication inhibition, cell cycle arrest, apoptosis, bystander killing of tumor cells
Therapy area
Oncology
Developer
Zai Lab Co., Ltd. (ZLAB)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07374848 Phase 1 Solid Tumors Recruiting ZLAB

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

SarcomasSolid Tumors

Other drugs acting on LRRC15

More from Zai Lab Co.

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the ZLAB page.

Follow ZLAB, the company behind ZL-6201

See ZLAB's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ZLAB catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.